Personalised medicine will only be successful when accurate diagnostic tests identify the patients who can benefit from targeted therapies and eventually reach the desired goal of prevention and prediction. The formidable challenges we are faced with in reaching this goal are numerous.

The scope of this conference is to connect high-level scientists across scientific domains, to support capacity building, and increase the impact of personalised medicine research on regulatory bodies, decision makers as well as the private sector.

The focus will be on the following:

    * Bring together researchers working on the latest scientific breakthrough developments of personalised medicine contributing to Europe’s research and innovation capacities;
    * Broaden the concept of personalised medicine from the genetically reductionist version to one that includes other types of markers;
    * Educate physicians and the public as a whole to these new developments. One of the major obstacles for making personalised medicine available for patients requires basic, translational, and also regulatory science, especially in the areas of ethical, legal and social issues;
    * To bridge science, policy makers and society in the area of Personalised Medicine.

Sessions will include:

    * The evolving regulatory system
    * Empowering the Patients
    * Future and Emerging Technologies in Personalised Medicine
    * Natural products as a source for new drugs
    * Constellation thinking in the diagnosis and therapy
    * Application of ICT personal health
    * New Targets and inhibitors based on epigenetics
    * Roundtables with stakeholders (Patients Associations, General Practitioners Associations, Clinician Associations)

Confirmed speakers include:

    * Mary Baker - European Brain Council, UK
    * María Berdasco - Bellvitge Biomedical Research Institute (IDIBELL), ES
    * Stephane Berghmans - European Medical Research Councils (EMRC), FR
    * Maurizio Botta - University of Siena, IT
    * Jef De Brabander - UT Southwestern Medical Center, US
    * Anne Bruinvels - Elixior, UK
    * Hervé Chneiweiss - French National Institute of Health and Medical Research (INSERM), FR
    * Richard Frackowiak - University of Lausanne, CH
    * A. Ganesan - University of East Anglia, UK
    * Ursula Gundert-Remy - Federal Institute for Risk Assessment, DE
    * Jacques Haiech - University of Strasbourg, FR
    * Manfred Jung - University of Freiburg, DE
    * Jonathan Knowles - Ecole Polytechnique Fédérale de Lausanne (EPFL), CH / Institute for Molecular Medicine Finland (FIMM), FI
    * Hans Lehrach - Max Planck Institute for Molecular Genetics, DE
    * Stavros Malas - Minister of Health, CY
    * Andrea Mattevi - University of Pavia, IT
    * Emmanuel Mikros - University of Athens, GR
    * Davor Milicic - University of Zagreb, HR
    * Christodoulos Nicolaou - Eli Lilly and Company, US
    * K.C. Nicolaou - The Scripps Research Institute, US
    * Irene Norstedt - European Commission, BE
    * David Nutt - Imperial College London, UK
    * Barbara Prainsack - Brunel University London, UK
    * Kamran Sayrafian - National Institute of Standards and Technology (NIST), US
    * Dina Simunic - University of Zagreb, HR
    * Albrecht von Müller - Parmenides Foundation, DE

A number of conference grants will be available for selected participants, in particular Early Stage Researchers.

Call for Expression of Interest